MAPT and Alzheimer disease: While these studies reported that higher LFPN-FC was associated with attenuated cognitive decline in attention and executive functioning in preclinical and prodromal AD, they also – consistent with our findings – indicated that LFPN-FC curbed cognitive decline in the setting of early tau pathology, independent of Aβ [8].